News und Analysen
ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the
Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
EQS-News: Medios AG: Successful completion of the acquisition of bbw – Significant expansion of compounding volume
Lysogene: Launch of a Process to Find Buyers or Investors and Request for Conversion of Safeguard Proceedings Into Reorganization Proceedings
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it has requested, jointly with
CI Global Asset Management Announces Reinvested Distributions
CI Global Asset Management (“CI GAM”) announces the following reinvested distributions (the “Reinvested Distributions”) in respect of certain ETFs listed below. In all cases, these Reinvested
Vistagen Advances Intellectual Property Program to Expand Patent Protection for PH94B to Include Treatment of Adjustment Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
CI Global Asset Management Announces Confirmed Annual Reinvested Capital Gains Distributions for CI ETFs
CI Global Asset Management (“CI GAM”) announces the confirmed annual reinvested capital gains distributions (the “Reinvested Distributions”) for the 2022 tax year for the CI ETFs listed below.
Following Previously Announced Confidential Submission of Draft Registration Statement for its U.S. Business, CI Financial Confirms Intent to Voluntarily Delist from the NYSE and Deregister with the U.S. Securities and Exchange Commission
CI Financial Corp. (TSX: CIX; NYSE: CIXX) (“CI”) announced today that it has submitted a formal notice to the New York Stock Exchange (“NYSE”) of its decision to voluntarily delist its common
Granite REIT Notice of Conference Call for Fourth Quarter and Year-End 2022 Results
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) expects to announce its financial results for the fourth quarter and year-ended December 31, 2022 after the close of
CI Financial Confirms Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of CI U.S. Holdings Inc.’s Common Stock
CI Financial Corp. (TSX: CIX; NYSE: CIXX) (“CI”), the parent of CI US Holdings Inc. (“CI US”), confirms that CI US has confidentially submitted a draft registration statement on Form S-1 with the
CI Financial Reports Record Total Assets of $384.9 Billion for November 2022
CI Financial Corp. (“CI”) (TSX: CIX, NYSE: CIXX) today reported preliminary total assets of $384.9 billion as at November 30, 2022, an all-time month-end high for the company. The total consisted
Vistagen to Acquire Pherin Pharmaceuticals
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
CI Global Asset Management to Launch Global and U.S. ETFs Focused on Managing Downside Volatility
CI Global Asset Management (“CI GAM”) today announced that it has received a receipt for the final prospectus of CI Global Minimum Downside Volatility Index ETF and CI U.S. Minimum Downside
Granite REIT Declares Distribution for December 2022
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2667 per stapled unit for the month of
Mannatech To Open Its Doors into Thailand in 2023
Mannatech, Incorporated (NASDAQ: MTEX), a leading provider of high-quality health and wellness products, is excited to announce its continued expansion into the ASEAN region, with the official
CI Global Asset Management Announces December 2022 Distributions for CI ETFs
CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month or quarter ending December 31, 2022 in respect of the CI ETFs. In all cases, the distribution
CI Financial Named a Top Employer for 2023
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) has been named one of Greater Toronto’s Top Employers for 2023, an award that recognizes firms with progressive human resources practices and
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
Vistagen, (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
CI Financial Announces Debenture Financing to Refinance Existing Indebtedness
CI Financial Corp. (“CI”) (TSX: CIX; NYSE: CIXX) announced today that it has entered into an agreement to sell debentures with an aggregate principal amount of $400 million, maturing on December 2
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced topline results from the Phase
GLORY launches TellerConcierge™; the future of assisted-service, multi-transactional branch banking
Today, GLORY announces its all new in-branch multi-transactional branch banking solution, TellerConcierge.
Designed to automate almost any banking transaction, TellerConcierge is a compelling
GLORY launches TellerConcierge™; the future of assisted-service, multi-transactional branch banking
Today, GLORY announces its all new in-branch multi-transactional branch banking solution, TellerConcierge.
Designed to automate almost any banking transaction, TellerConcierge is a compelling
GLORY launches TellerConcierge™; the future of assisted-service, multi-transactional branch banking
Today, GLORY announces its all new in-branch multi-transactional branch banking solution, TellerConcierge.
Designed to automate almost any banking transaction, TellerConcierge is a compelling
GLORY launches the GLR Series of next generation Teller Cash Recyclers
Today, Glory announces the latest solution in its new GLR series of Teller Cash Recyclers (TCRs) the GLR-200. Building upon the successful launch of GLR-100 in August this year, the new Roll